Verve Therapeutics Statistics
Share Statistics
Verve Therapeutics has 84.66M shares outstanding. The number of shares has increased by 5.22% in one year.
| Shares Outstanding | 84.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.78% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 63.10M |
| Failed to Deliver (FTD) Shares | 509 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 17.23M, so 20.35% of the outstanding shares have been sold short.
| Short Interest | 17.23M |
| Short % of Shares Out | 20.35% |
| Short % of Float | 27.31% |
| Short Ratio (days to cover) | 16.17 |
Valuation Ratios
The PE ratio is -4.47 and the forward PE ratio is -2.29.
| PE Ratio | -4.47 |
| Forward PE | -2.29 |
| PS Ratio | 76.08 |
| Forward PS | 36.1 |
| PB Ratio | 1.49 |
| P/FCF Ratio | -5.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Verve Therapeutics Inc. has an Enterprise Value (EV) of 763.33M.
| EV / Earnings | -3.82 |
| EV / Sales | 64.92 |
| EV / EBITDA | -3.51 |
| EV / EBIT | -3.42 |
| EV / FCF | -4.81 |
Financial Position
The company has a current ratio of 17.24, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.24 |
| Quick Ratio | 17.24 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.67 |
| Cash Flow / Debt | -14.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on capital (ROIC) is -33.13%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | -0.27% |
| Return on Capital (ROIC) | -33.13% |
| Revenue Per Employee | 46.11K |
| Profits Per Employee | -784.58K |
| Employee Count | 255 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 275.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -58.73% in the last 52 weeks. The beta is 1.76, so Verve Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.76 |
| 52-Week Price Change | -58.73% |
| 50-Day Moving Average | 5.67 |
| 200-Day Moving Average | 6.79 |
| Relative Strength Index (RSI) | 52.45 |
| Average Volume (20 Days) | 1.42M |
Income Statement
In the last 12 months, Verve Therapeutics had revenue of $11.76M and earned -$200.07M in profits. Earnings per share was $-3.12.
| Revenue | 11.76M |
| Gross Profit | 6.30M |
| Operating Income | -223.12M |
| Net Income | -200.07M |
| EBITDA | -217.67M |
| EBIT | -223.12M |
| Earnings Per Share (EPS) | -3.12 |
Balance Sheet
The company has $206.18M in cash and $74.91M in debt, giving a net cash position of $131.27M.
| Cash & Cash Equivalents | 206.18M |
| Total Debt | 74.91M |
| Net Cash | 131.27M |
| Retained Earnings | -544.30M |
| Total Assets | 663.91M |
| Working Capital | 513.82M |
Cash Flow
In the last 12 months, operating cash flow was -$149.55M and capital expenditures -$9.28M, giving a free cash flow of -$158.83M.
| Operating Cash Flow | -149.55M |
| Capital Expenditures | -9.28M |
| Free Cash Flow | -158.83M |
| FCF Per Share | -2.47 |
Margins
Gross margin is 53.61%, with operating and profit margins of -1.90K% and -1.70K%.
| Gross Margin | 53.61% |
| Operating Margin | -1.90K% |
| Pretax Margin | -1.70K% |
| Profit Margin | -1.70K% |
| EBITDA Margin | -1.85K% |
| EBIT Margin | -1.90K% |
| FCF Margin | -1.35K% |
Dividends & Yields
VERV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -54.55% |
| FCF Yield | -32.8% |
Analyst Forecast
The average price target for VERV is $24.5, which is 328.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.5 |
| Price Target Difference | 328.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 0.38 |
| Piotroski F-Score | 3 |